AU2008269513B2 - 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors - Google Patents

1-cyanocyclopropyl-derivatives as cathepsin K inhibitors Download PDF

Info

Publication number
AU2008269513B2
AU2008269513B2 AU2008269513A AU2008269513A AU2008269513B2 AU 2008269513 B2 AU2008269513 B2 AU 2008269513B2 AU 2008269513 A AU2008269513 A AU 2008269513A AU 2008269513 A AU2008269513 A AU 2008269513A AU 2008269513 B2 AU2008269513 B2 AU 2008269513B2
Authority
AU
Australia
Prior art keywords
tetrahydro
pyrido
cyanocyclopropyl
cyclohexanecarboxamide
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008269513A
Other languages
English (en)
Other versions
AU2008269513A1 (en
Inventor
Alexander Graham Dossetter
Nicola Murdoch Heron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008269513A1 publication Critical patent/AU2008269513A1/en
Application granted granted Critical
Publication of AU2008269513B2 publication Critical patent/AU2008269513B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2008269513A 2007-06-26 2008-06-24 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors Ceased AU2008269513B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94617807P 2007-06-26 2007-06-26
US60/946,178 2007-06-26
US4284008P 2008-04-07 2008-04-07
US61/042,840 2008-04-07
PCT/GB2008/050486 WO2009001129A1 (en) 2007-06-26 2008-06-24 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors

Publications (2)

Publication Number Publication Date
AU2008269513A1 AU2008269513A1 (en) 2008-12-31
AU2008269513B2 true AU2008269513B2 (en) 2011-06-16

Family

ID=39761131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008269513A Ceased AU2008269513B2 (en) 2007-06-26 2008-06-24 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors

Country Status (19)

Country Link
US (1) US8008279B2 (https=)
EP (1) EP2170879B1 (https=)
JP (1) JP2010531344A (https=)
KR (1) KR20100039862A (https=)
CN (1) CN101687864A (https=)
AR (1) AR067156A1 (https=)
AU (1) AU2008269513B2 (https=)
BR (1) BRPI0813306A2 (https=)
CA (1) CA2689945A1 (https=)
CL (1) CL2008001899A1 (https=)
CO (1) CO6251264A2 (https=)
EC (1) ECSP109882A (https=)
IL (1) IL202519A0 (https=)
NZ (1) NZ581719A (https=)
PE (1) PE20090841A1 (https=)
RU (1) RU2470023C2 (https=)
TW (1) TW200911806A (https=)
UY (1) UY31180A1 (https=)
WO (1) WO2009001129A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP5666036B2 (ja) * 2008-01-25 2015-02-04 メディベイション テクノロジーズ， インコーポレイテッド 新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
WO2010036998A2 (en) 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
AU2009336040B2 (en) * 2008-12-18 2015-07-16 Merck Patent Gmbh Tricyclic azaindoles
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
PH12012500775A1 (en) 2009-10-21 2012-11-26 Boehringer Ingelheim Int Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
WO2011084433A2 (en) 2009-12-17 2011-07-14 Abbott Laboratories Aza-bridged ring-fused indoles and indolines
US8524703B2 (en) 2009-12-17 2013-09-03 Abbvie Inc. Bridgehead amine ring-fused indoles and indolines
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8791132B2 (en) 2011-02-18 2014-07-29 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
CA2852173A1 (en) * 2012-01-11 2013-07-18 Lilli Anselm Macrocyclic amides as protease inhibitors
CN103086923B (zh) * 2013-01-21 2014-04-23 吉林大学 肼腈类组织蛋白酶k抑制剂及其在治疗骨质疏松症方面的应用
CN105593230B (zh) * 2013-10-08 2018-07-06 默沙东公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
WO2016027285A2 (en) * 2014-08-22 2016-02-25 Alkem Laboratories Ltd. Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors
CN105837479B (zh) * 2016-04-05 2017-10-27 吉林大学 肼腈类组织蛋白酶k抑制剂及其在制备治疗骨关节炎药物中的应用
EP3600451B1 (en) * 2017-03-29 2025-12-24 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
CN118742549A (zh) * 2022-01-21 2024-10-01 山东新时代药业有限公司 一种组织蛋白酶k抑制剂与其制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048123A1 (en) * 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2379747C (en) * 1999-07-30 2008-09-23 Boehringer Ingelheim Pharmaceuticals, Inc. Novel succinate derivative compounds useful as cysteine protease inhibitors
DE60132975T2 (de) * 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
AU2001245764A1 (en) 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
CA2439415C (en) 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
RU2278863C2 (ru) * 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048123A1 (en) * 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors

Also Published As

Publication number Publication date
RU2470023C2 (ru) 2012-12-20
PE20090841A1 (es) 2009-08-02
BRPI0813306A2 (pt) 2017-05-16
ECSP109882A (es) 2010-02-26
WO2009001129A1 (en) 2008-12-31
AU2008269513A1 (en) 2008-12-31
JP2010531344A (ja) 2010-09-24
IL202519A0 (en) 2010-06-30
CN101687864A (zh) 2010-03-31
RU2010101279A (ru) 2011-08-10
WO2009001129A9 (en) 2010-02-04
UY31180A1 (es) 2009-01-30
EP2170879B1 (en) 2013-01-16
TW200911806A (en) 2009-03-16
NZ581719A (en) 2011-08-26
KR20100039862A (ko) 2010-04-16
CL2008001899A1 (es) 2009-07-17
EP2170879A1 (en) 2010-04-07
US20090012077A1 (en) 2009-01-08
CA2689945A1 (en) 2008-12-31
AR067156A1 (es) 2009-09-30
US8008279B2 (en) 2011-08-30
CO6251264A2 (es) 2011-02-21

Similar Documents

Publication Publication Date Title
AU2008269513B2 (en) 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors
ES2930585T3 (es) Inhibidores de TYK2 y usos de los mismos
US20240025907A1 (en) QUINAZOLINE PAN-KRas INHIBITORS
US20250376483A1 (en) Prodrugs of pan-kras inhibitors
WO2022221528A2 (en) Kras g12c inhibitors
US20220194961A1 (en) Tetrahydropyridopyrimidine pan-kras inhibitors
CN112094269A (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
ES2793199T3 (es) Derivados de tetrahidroimidazopiridina como moduladores de la actividad de TNF
EP2155743A1 (en) Imidazoquinolines with immuno-modulating properties
EP1926730A1 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
JP2005516053A (ja) 縮合複素環式化合物
CN112584898B (zh) P2x3受体拮抗剂
US20230113609A1 (en) Sstr5 antagonists
JP2013526591A (ja) ピラゾール誘導体
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
JP2009500405A (ja) 炎症性および免疫疾患の処置のためのｐｄｅ４阻害剤としてのピリドピリミジン誘導体
AU2021395816B2 (en) N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma
US5498611A (en) Ellipticine compounds
CN120752240A (zh) 作为eIF4E抑制剂的化合物和组合物及其用途
WO2009001128A1 (en) 1,2-cycl0hexane dicarboxamides as cathepsin inhibitors
EP4688768A1 (en) Novel mettl3 inhibitors and use thereof in therapy
WO2022189387A1 (en) Tricyclic pyridines as cyclin-dependent kinase 7 (cdk7) inhibitors
SA08290382B1 (ar) مشتقات 1- سيانوسيكو بروبيل متضمنة نظام حلقة ثلاثي حلقي وإستخدامها في العلاج
WO2025154017A1 (en) Usp28 inhibitors
WO2024222807A1 (en) Novel macrocyclic heteroaryl derivatives as kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired